Functional and Phenotypic Characterization of CD57+CD4+ T Cells and Their Association with HIV-1-Induced T Cell Dysfunction

Brent E. Palmer, Naomi Blyveis, Andrew P. Fontenot and Cara C. Wilson

*J Immunol* 2005; 175:8415-8423; doi: 10.4049/jimmunol.175.12.8415
http://www.jimmunol.org/content/175/12/8415

References

This article cites 40 articles, 21 of which you can access for free at:
http://www.jimmunol.org/content/175/12/8415.full#ref-list-1

Subscription

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Functional and Phenotypic Characterization of CD57<sup>+</sup>CD4<sup>+</sup> T Cells and Their Association with HIV-1-Induced T Cell Dysfunction<sup>1</sup>

Brent E. Palmer, Naomi Blyveis, Andrew P. Fontenot, and Cara C. Wilson<sup>2</sup>

HIV-1 replication is associated with reduced or absent HIV-1-specific CD4<sup>+</sup> T cell proliferation and skewing of HIV-1-specific CD4<sup>+</sup> T cells toward an IFN-γ-producing, CCR7<sup>+</sup> phenotype. The CCR7<sup>+</sup> T cell population is heterogeneous and can be subdivided based on the expression of CD57. Although CD57 expression on CD8<sup>+</sup> T cells is associated with proliferation incompetence and replicative senescence, less is known about the function of CD57-expressing CD4<sup>+</sup> T cells. In this study, the frequency, phenotype, and function of CD57<sup>+</sup>CD4<sup>+</sup> T cells were evaluated in 25 HIV-1-infected subjects and 10 seronegative controls. CD57<sup>+</sup>CD4<sup>+</sup> T cells were found to be proliferation incompetent, even after strong mitogen stimulation. Percentages of CD4<sup>+</sup> T cells that expressed CD57 were significantly higher in untreated HIV-1-infected subjects than in HIV-1-seronegative donors, and CD57 expression did not normalize in subjects receiving at least 6 mo of effective antiretroviral therapy. CD57 was predominately expressed on the CCR7<sup>+</sup> fraction of the CD4<sup>+</sup> T cell compartment and accounted for the majority of cells in the CCR7<sup>+</sup>CD45RA<sup>+</sup> population from untreated HIV-1-infected subjects. HIV-1-specific CD4<sup>+</sup> T cells producing only IFN-γ had the highest expression of CD57, whereas few cells producing IL-2 alone expressed CD57. These findings further define a novel population of proliferation-incompetent CD4<sup>+</sup> T cells that are generated in the presence of chronic Ag exposure. A better understanding of the generation and persistence of CD57<sup>+</sup> T cells in HIV-1 infection could provide important insights into the immunopathogenesis of this disease. The Journal of Immunology, 2005, 175: 8415–8423.

Functionally distinct T cell populations can be defined by the expression of specific cell surface Ags. Numerous studies describe associations between T cell surface phenotype and function, and this information is extensively used to track and delineate HIV-1 pathogenesis (1–7). CD57, a surface molecule expressed on T and NK cells, is a marker with functional associations. Recently, it was shown that a subpopulation of CD8<sup>+</sup> T cells expressing CD57 were proliferation incompetent (8). These cells were terminally differentiated and underwent apoptosis upon T cell activation (7–9). The expression of CD57 on the surface of CD8<sup>+</sup> T cells is also linked with chronic immune activation, and increased numbers of CD8<sup>+</sup> T cells expressing CD57 have been associated with HIV-1 and other persistent viral infections (7, 9, 10). Expansions of CD4<sup>+</sup> T cells expressing CD57 are associated with a number of chronic pathological conditions such as tuberculosis, malaria, rheumatoid arthritis, and HIV-1 infection (11–15). However, the function of these cells is not well characterized, and the association of this cell population with HIV-1 disease remains poorly understood.

HIV-1 replication is associated with profound changes in CD4<sup>+</sup> T cell function, including reduced proliferative responses to recall Ags and mitogens (16, 17). Changes in CD4<sup>+</sup> T cell function are associated with changes in memory T cell maturation state that take place in the presence of viral replication and chronic Ag exposure. We and others (6, 18) have shown that HIV-1 replication skews HIV-1-specific CD4<sup>+</sup> T cells away from an IL-2-producing, proliferation competent, CCR7<sup>+</sup> central memory T cell (Tcm) phenotype, toward an IFN-γ-producing, CCR7<sup>+</sup> effector memory T cell (Tem) phenotype. Skewing of the HIV-1-specific CD4<sup>+</sup> T cell population is directly correlated with increased HIV-1 viral load and decreased HIV-1-specific proliferation (6). CD4<sup>+</sup> T cell proliferative responses are partially restored with the suppression of HIV-1 replication with antiretroviral therapy (ART), and the recovery of proliferation in these subjects is in part due to an increase in the frequency of IL-2-producing CCR7<sup>+</sup>CD45RA<sup>+</sup>CD4<sup>+</sup> T cells (19, 20). Interestingly, the increased proliferation potential of adoptively transferred CCR7<sup>+</sup>CD4<sup>+</sup> T cells was associated with their ability to control lymphocytic choriomeningitis virus replication in a mouse model of chronic viral infection (21). Studies of the proliferative potential of virus-specific CD4<sup>+</sup> T cells associated strong proliferative responses with control of viral replication, although this has not been conclusively shown in HIV-1 disease (22, 23).

It was recently proposed that CCR7<sup>+</sup> effector memory CD4<sup>+</sup> T cells (Tem) may be divided into at least two subpopulations based on proliferative capacity (18). This model holds that when naive CD4<sup>+</sup> T cells are initially exposed to Ag, they develop into an early CCR7<sup>+</sup> effector population (Tem1) with strong proliferative potential, subsequently reverting to CCR7<sup>+</sup>Tem cells that persist over time when Ag burden is low or absent. If Ag exposure remains high and constant, as in the case of untreated HIV-1 infection, these “Tem1” CD4<sup>+</sup> T cells may instead develop into a more...
differentiated "Tem2" effector population, which is able to produce IFN-γ but lacks the capacity to produce IL-2, and thus, the ability to self-renew. HIV-1-specific CCR7+ CD4+ T cells from viremic subjects, in whom Ag levels remain high, are only able to produce IFN-γ, whereas those from aviremic subjects can produce both IFN-γ and IL-2 (6, 18). We hypothesized that the expression of CD57 on CD4+ T cells might be used as a marker to differentiate Tem1 from Tem2 and as an indicator to assess the functionality of the T cell compartment in HIV-1-infected subjects.

In this study, we examined the frequency, phenotype, and functional properties of Ag-specific CD57+ T cells in untreated, viremic HIV-1-infected subjects as well as in infected subjects whose viral loads were suppressed with ART using multiparameter flow cytometry, intracellular cytokine staining, and CFSE staining. We conclusively demonstrate that CD57+ CD4+ T cells can produce IFN-γ but are unable to proliferate or produce IL-2, even when stimulated with a powerful mitogen. We also show that CD4+ CD57+ T cells are expanded in HIV-1-infected subjects, and that CD57+ T cells constitute a high proportion of the CCR7- T cell population, especially in subjects with untreated HIV-1 disease. These data suggest that the expression of CD57 on CD4+ T cells may be an important phenotypic marker to assess the functional competence of the CD4+ T cell compartment.

Materials and Methods

Study population

HIV-1-infected study subjects were selected from a cohort of HIV-1-infected individuals followed in the Adult Infectious Diseases Group Practice at the University of Colorado Health Sciences Center. Twenty-five HIV-1-infected subjects enrolled into two clinical cohorts based upon their treatment status: highly active ART (HAART)-suppressed (HS) or treatment non-suppressed (TN) groups based on having a screening peripheral CD4 cell count, 594 cells/μl to self-renew. HIV-1-specific CCR7-CD4+ T cells are expanded in HIV-1-infected subjects, and that CD57+ T cells may be an important phenotypic marker to assess the functional competence of the CD4+ T cell compartment.

Proliferation assay

Assays were performed on either whole PBMC or with combinations of sorted CD4+ T cells and CD4-depleted PBMC. Cells were labeled with CFSE (Molecular Probes) by incubating 6 x 10^6 cells in a 3-μM solution of CFSE in HBSS for 20 min at 37°C followed by two washes before incubation with Ag. Sorted CD4 enriched CD4+ or CD57+ CD45RA- and CD57+ CD45RA+ were added at a 1:1 ratio with CD4+ T cell-depleted PBMC. Both whole PBMC and the sorted PBMC were plated at 1 x 10^6 cells/ml, stimulated with 5 μg/ml PHA (REME), and cultured for 4 days in RPMI 1640 plus 10% human serum at 37°C in a humidified 5% CO_2 atmosphere. On day 4, cells were gently removed from the plates with PBS and stained with 1% BSA, and surface stained with anti-CD4 allophycocyanin Cy7 (Caltag Laboratories), anti-CD8 allophycocyanin (BD Pharmingen), anti-CD57 PE (BD Pharmingen), and anti-CD3 PE-TR (Beckman Coulter) for 30 min at 4°C. Cells were washed again and resuspended in 1% formaldehyde. In the whole PBMC cultures, the percentage of CD57+ and CD57+ CD4+ T cells that proliferated was determined by first gating on CD3+ CD4+ CD57+ and CD3+ CD4+ CD57+ subpopulations, then determining the percentage of CFSElow cells in each subpopulation. CD4+ T cells from unstimulated cultures were used to set the gate for the determination of the percentage of CFSEhigh cells in the PHA-stimulated cultures.

Apoptosis assay

PBMC were stained directly ex vivo and after 24 h in culture with and without PHA stimulation. PBMC were placed at 1 x 10^6 cells/ml in 24-well plates in RPMI 1640 plus 10% human serum with or without 1 μg/ml PHA (Sigma-Aldrich) and incubated for 24 h. PBMC were washed and incubated with unlabeled anti-CD57 mAb (BD Pharmingen) for 30 min at 4°C, washed once with PBS containing 1% BSA, and then stained with the secondary anti-mouse IgM label with biotin for 30 min at 4°C. Cells were washed again with PBS-BSA and stained with anti-CD4 (allophycocyanin Cy7; BD Pharmingen), anti-CD3 PE-TR (Beckman Coulter), and streptavidin-PE. Washed cells were then resuspended in 1 x annexin V buffer and incubated with annexin V-FTTC (BD Pharmingen) for 15 min in the dark at room temperature. Two hundred microliters of annexin V buffer was added, and the samples were analyzed immediately on the FACS ARIA.

Peptides

HIV-1 Gag peptides (122 peptides) consisted of 15mers overlapping by 11 aas and corresponding to sequences of clade B HIV. B X B2 strain HIV-1 (National Institutes of Health AIDS Research and Reference Reagent Program; catalog no. 5107). HIV-1 Pol peptides (100 peptides) were 20mers overlapping by 10 aas corresponding to clade B strain H X B2R (National Institutes of Health AIDS Research and Reference Reagent Program; catalog no. 4358), and HIV-1 Nef clade B peptides (49 peptides; National Institutes of Health AIDS Research and Reference Reagent Program; catalog no. 5189) were 15mers overlapping by 11 aas. Peptides were individually resuspended at 100 mg/ml in DMSO, then pooled into a group containing all Gag, Pol, and Nef peptides.

T cell stimulations for Ag-specific cytokine production

The frequency of Ag-specific, IFN-γ and IL-2-producing T cells in PBMC was determined using a previously reported method, with minor modifications (10). Briefly, 2.5 x 10^6 PBMCs were plated in 12 x 75 mm culture tubes containing 3 μg/ml anti-CD28 and -CD49d Abs (BD Biosciences) in RPMI 1640 plus 10% human serum at 37°C. Cells were pulsed with 1 μg/ml PHA (REMEL), and 2.5 x 10^5 HIV-1 Gag peptides were added, and the samples were analyzed immediately on the FACS ARIA.

Immunofluorescence staining of stimulated T cells

Stimulated PBMC were washed and then surfaced stained with unlabeled anti-CCR7 mAb (BD Pharmingen) for 30 min at 4°C, washed once with PBS containing 1% BSA, and stained with the secondary anti-mouse IgM label with biotin for 30 min at 4°C. Cells were washed once with PBS-BSA and stained with anti-CD4 (allophycocyanin Cy7; BD Pharmingen), anti-CD3 PE-TR (Beckman Coulter), anti-CD8 (Alexa Flour 405; Caltag Laboratories), anti-CD57 FITC (BD Pharmingen), anti-CD45RA (PE Cy5;
IFN- 
Pharmingen). This was accomplished by adding both CD107a and b (FITC; 
mimic their normal physiological environment as well as to pro-
Allophycocyanin, and Annexin V for 30 min at 4°C. Permeabilized cells were 
resuspended in 1% formaldehyde.

Flow cytometric acquisition and analysis
Ten-parameter flow cytometry was performed using a FACSalibur 
FITC or CFSE, PE, TR, PE Cy5, PE Cy7, allophycocyanin, 
D'HE/PECy7, and Alexa Fluor 405 were used as fluorophores. At least 
5 × 10^6 live CD3^+ lymphocytes were collected for the Ag-specific 
analysis. The data files were analyzed using Diva software (BD Bio-
sciences). When PBMC were cultured with only medium and costimu-
lar cytokines, the background frequency of cytokine-pro-
ducing CD4^+ T cells, the median response for IFN-γ only was 0.01% 
(range, 0.0–0.06%), IFN-γ+IL-2 was 0.0% (range, 0.0–0.03%), and for IL-2 
only was 0.04% (range, 0.0–0.15%). Analysis of CD8^+ T cells was 
performed by gating on the CD3^+ CD4^− T cells because anti-CD8 Ab was 
not added in all experiments. However, ~50% of the patient samples were 
stained with anti-CD8, and within a subject the CD3^+ CD4^− population 
was almost all CD8^−, confirming the validity of our negative gating 
strategy.

Statistical analysis
The Mann-Whitney U test and the Kruskal-Wallis test with pairwise 
comparison (Dunn multiple comparison test) were used to determine signif-
cance of differences between subject groups. A Spearman correlation test 
was performed to analyze the association between CD57^+ CD4^+ T cells.

Results
CD57 expression on CD4^+ T cells is associated with 
proliferation incompetence
Because it has been shown that CD57^+ CD8^+ T cells have reduced 
proliferative capacity, we first sought to determine whether this 
held true for CD4^+ T cells expressing CD57. CD57^+ CD4^+ T cell 
proliferation was initially examined using bulk PBMC cultures from 
ten healthy HIV-1-seronegative subjects. CFSE-labeled 
PBMC were incubated with PHA for 3 days, and the percentage of 
CD57^+ CD4^+ T cells that were CFSE^low was calculated as 
described in Materials and Methods. Fig. 1A shows that CD4^+ T 
cells that expressed CD57 proliferated significantly less well than did 
those not expressing CD57. The median percentage of 
CFSE^low, proliferating CD57^+ CD4^+ T cells was 21.5% (range, 14.3– 
54.4%), whereas the median percentage of proliferating 
CD57^− CD4^+ T cells was 65.75% (range, 52–88%; p < 0.0001). 
Significantly fewer CD57^+ CD4^+ T cells also proliferated in the 
(Apoptosis induced by CD57)

Fig. 2A shows a significantly higher percentage of CD4^+ T cells expressing 
CD57 stained with annexin V than cells not expressing 
CD57 directly ex vivo (p = 0.04). The median percentage of 
annexin V-positive CD4^+ T cells expressing CD57 was 15.9% 
(range, 4.3–27.8%) compared with 3.1% (range, 1.5–5.6%) for 
CD57^− cells. Fig. 2B shows that when PBMC were cultured for 
24 h without stimulation, CD4^+ T cells expressing CD57 also had 
significantly higher percentages of annexin V staining than did 
CD57^− cells (p = 0.003). After 24 h in culture, the median 
percentage of annexin V-positive CD4^+ T cells expressing CD57 was 
38.2% (range, 16.3–53.4%) compared with 13.6% (range, 
4–25.8%) of CD57^− cells. To determine the level of activation-
duced apoptosis, PBMC were stimulated for 24 h with PHA. 
Stimulation substantially increased the level of annexin V staining on 
all CD4^+ T cells, but again, more CD57^− expressing cells stained 
annexin V-positive than did CD57^+ cells (p = 0.006; data 
not shown). These data suggest that CD57 expression on CD4^+ T 
cells is associated with an increased rate of spontaneous as well as 
activation-induced apoptosis.

HIV-1 infection is associated with increased percentages of 
CD57^+ T cells in the peripheral blood
CD57 expression on T cell subpopulations from 25 HIV-1-infected 
subjects and 10 seronegative control subjects was measured by 
flow cytometry. Fig. 3A shows that the median percentage of 
CD4^+ T cells that expressed CD57 in HIV-1-infected subjects 
(12.3%; range, 2.0–63.4%) was significantly higher than in sero-
egative subjects (4.6%; range, 2.6–15.6%; p = 0.004). As shown in 
Fig. 3B, the HIV-1-infected cohort was subdivided into antiretro-
viral TN and HS subjects to determine whether suppression of 
virological replication had an effect on CD57 expression. The median 
percentage of CD4^+ T cells expressing CD57 in the TN and HS 
cohort was 12.4% (range, 2–63.4%) and 11.5% (range, 3.6–26.5%), 
respectively. Despite the fact that several viremic subjects 
expressed CD57 on >25% of their CD4^+ T cells, no significant 
difference in CD57 expression was seen between these groups in the
Although this finding could indicate that CD57 expression on CD4 T cells does not completely normalize after ART, interpretation of these results is limited by a small sample size. These data show that there is an increased percentage of CD4 T cells expressing CD57 in HIV-1-infected subjects, and that suppression of HIV-1 replication does not result in the complete normalization of CD57 expression in this T cell compartment even after 6 mo of treatment.

CD57 is expressed on more differentiated Tem cell populations

CD57 expression has been associated with terminal differentiation of CD8 T cells, but less has been reported about the expression of this marker on CD4 T cells. CD57 expression was analyzed on memory CD3 CD4 T cell populations in TN, HS, and HIV-seronegative subjects using multicolor flow cytometry (Fig. 4). CD45RA and CCR7 expression was used to divide the memory T cell compartment for each subject into distinct populations: Tcm (CD45RA CCR7), Tem (CD45RA CCR7), and terminally differentiated effector memory cells (Temtd) (CD45RA CCR7) (25, 26). Representative examples of CD57 staining on the three memory CD4 T cell populations, as defined by the expression of CCR7 and CD45RA, are shown in Fig. 4A. CD57 was infrequently expressed on CCR7 CD45RA central memory CD4 T cells; among all subjects, a median of 4.8% of cells expressed CD57, and there was no statistically significant difference in CD57 expression among all subjects, a median of 4.8% of cells expressed CD57, and there was no statistically significant difference in CD57 expression
on CD4⁺ Tcm cells between subject groups (Fig. 4B). CD57 was expressed on a higher percentage of CD4⁺CCR7⁻CD45RA⁻ Tem cells, with a median of 18.5% for all subjects. The median percentage of CD57⁺CD4⁺ Tem cells was 26.2% (range, 3.7–52.7%) in the TN group, 16.0% (range, 5.8–45.0%) in the HS group and 9.6% (range, 0.18–37.5%) in the HIV-1-seronegative group (Fig. 4B). Although the median percentage of CD4⁺ Tem cells expressing CD57 in the TN group was almost three times higher than in the HIV-1-seronegative control group, this difference was not statistically significant, perhaps due to the broad range of CD57 expression on CD4⁺ Tem cells within each cohort. CD57 expression on the CCR7⁻CD45RA⁺CD4⁺ Temtd cells was the highest of the memory subpopulations, with a median of 42.7% (range, 0.28–91.5%) for all subjects. The median percentage of CD57⁺CD4⁺ Temtd cells was 68.3% (range, 7.8–91.5%) in the TN group, 35.6% (range, 10.7–80.9%) in the HS group, and 28.1% (range, 0.28–48.7%) in the HIV-1-seronegative group. The difference in percentages of CD57⁺CD4⁺ Temtd cells between the TN and HIV-seronegative groups was found to be statistically significant (p = 0.02). Interestingly, a significant direct correlation was found between the percentage of CD4⁺CD57⁺ Temtd cells and plasma viral load (r = 0.53; p = 0.02; data not shown) within the HIV-1-infected subject cohort. In addition, we found that intracohort variation in CD57 expression on the memory CD4⁺ T cell populations was higher for the HIV-1-infected groups than the seronegative controls (p = 0.0002 and p = 0.0003, respectively, vs p = 0.01).

**CD57 is predominantly expressed on IFN-γ-producing, Ag-specific T cells**

We have previously shown that there is a discordance between HIV-1-specific IFN-γ-producing CD4⁺ T cells and HIV-1-specific CD4⁺ T cell proliferation in untreated HIV-1-infected subjects with progressive disease (19). Additionally, a direct correlation between the percentage of HIV-1-specific IL-2-producing cells and CD4⁺ T cell proliferation has been described (18, 27). We hypothesized that CD57 expression would also vary on distinct cytokine-producing CD4⁺ T cell populations (single IFN-γ, single IL-2, and double IFN-γ/IL-2), and that CD57 expression might reflect their known proliferative potential. We also wanted to determine...
whether HIV-1 replication induced changes in CD57 expression on cytokine-producing T cells of other specificities. To address these questions, we analyzed CD57 expression on HIV-1- and CMV-specific as well as SEB-stimulated T cells that produced either IFN-γ only, IFN-γ and IL-2, or IL-2 only from all 25 HIV-1-infected subjects. A representative example of CD57 expression on cytokine-producing CD4⁺ T cells after stimulation with HIV-1 peptides is shown in Fig. 5A. Because the frequency of HIV-1-specific CD4⁺ T cells in peripheral blood tends to be low, we only examined the expression of CD57 on cytokine-producing cells with frequencies ≥0.04% to ensure an adequate number of events for a valid analysis. Additionally, due to these low frequency responses and the nature of multicolor parameter flow, which subdivides small populations into even smaller subsets, 5 × 10⁶ PBMC from HIV-1-infected subjects were simultaneously incubated with Gag, Pol, and Nef overlapping peptides to stimulate a maximal number of cytokine-producing cells for detailed multiparametric analysis.

Examination of CD57 expression on HIV-1-specific CD4⁺ T cells from these subjects, as depicted in Fig. 5B, revealed that the median percentage of HIV-1-specific IFN-γ-producing cells (58.7%; range, 20.8–77.5%) expressing CD57 was significantly higher than that of the IFN-γ/IL-2- (42.08%; range, 36.4–47.3%) or IL-2- (19.35%; range, 2.1–51.6%) producing cells (p = 0.0007). Interestingly, the distribution of CD57 on the three discrete cytokine-secreting T populations was mirrored in the CMV-specific CD4⁺ T cell response in HIV-1-infected subjects. Evaluation of CD57 expression on CMV-specific CD4⁺ T cells from these subjects revealed that the median percentage of CMV-specific IFN-γ/CD4⁺ T cells expressing CD57 (60.5%; range, 38.3–80.3%) was also much higher than that of the IFN-γ/IL-2- cells (35.6%; range, 20–61.3%) or IL-2 only (22.2%; range, 4.1–47.3%) producing cells (p < 0.0001). To examine the expression of CD57 on superantigen-induced, cytokine-producing CD4⁺ T cells, SEB was used as a stimulus. CD57 expression on SEB-stimulated CD4⁺ T cells from these subjects revealed that the median percentage of SEB-stimulated IFN-γ-producing cells expressing CD57 (56.4%; range, 16.6–77.8%) was also much higher than that of the IFN-γ/IL-2- cells (16.6%; range, 5.6–55.5%) or IL-2 only (4.8%; range, 1.1–10.5%) producing cells (p < 0.0001). There was no significant difference between TN and HS subjects in the percentage of HIV-1-specific cytokine-producing CD4⁺ T cells that expressed CD57 (TN, ○; HS, ◇) (Fig. 5). Comparison between HIV-1-, CMV-, and SEB-stimulated IFN-γ-producing cells also revealed no difference in CD57 expression (p = 0.57). However, when CD4⁺ IL-2-producing T cells were examined, a significantly greater percentage of both HIV-1- and CMV-specific CD4⁺ T cells expressed CD57 compared with SEB-stimulated CD4⁺ T cells (p = 0.002). Further analysis revealed that SEB-responsive IL-2-producing CD4⁺ T cells were comprised of more CCR7⁺, CD45RA⁻ (naive), and CCR7⁻CD45RA⁻ (Tem) cells than either CMV- or HIV-specific IL-2-producing CD4⁺ T cells, which were skewed toward a CCR7⁻CD45RA⁻ (Tem) phenotype (data not shown). These data show that CD57 is expressed on a high percentage of CD4⁺ T cells capable of producing only IFN-γ, regardless of Ag specificity.

Although no significant difference between TN and HS subjects was seen in CD57 expression on HIV-1-specific CD4⁺ T cells expressing a particular cytokine profile, we theorized that CD57 expression on total HIV-1-specific T cells from untreated subjects would be greater due to a shift toward IFN-γ production in the presence of viremia. To address this, we first examined the distribution of HIV-1-specific IFN-γ and IL-2-producing CD4⁺ T cells. Fig. 5C shows the distribution of HIV-1-specific CD4⁺ cytokine-producing T cells for TN (n = 9) and HS (n = 13) subjects. The
mean percentage of HIV-1-specific CD4+ T cells from TN subjects producing single IFN-γ or IL-2 and double-positive IFN-γ/IL-2 was 63.1, 8.9, and 27.8%, respectively. In the HS cohort, the mean percentage of HIV-1-specific CD4+ T cells producing single IFN-γ or IL-2 and double-positive IFN-γ/IL-2 was 37.7, 20.5, and 41.7%, respectively. ANOVA (Kruskal-Wallis test) determined that there were significant differences in the proportion of HIV-1-specific CD4+ T cells (data not shown). The median percentage of HIV-1-specific CD4+CD8+ T cells in TN subjects was 29.7%, whereas CD57 was expressed on a median of 21% in HS subjects. Although CD57 expression was almost one third lower in treated subjects, this difference was not found to be statistically significant (data not shown).

A positive correlation exists between CD57-expressing CD4+ and CD8+ T cells

Because CD57-positive and CD57-negative T cells are both found at higher levels in HIV-1-infected subjects than in uninfected controls, we next sought to determine whether associations existed between the frequencies of these two cell populations in the peripheral blood and with markers of disease progression. A strong positive correlation was found between CD57-expressing total CD4+ and CD8+ T cell populations in the peripheral blood of HIV-1-infected patients \( (r = 0.71; p < 0.0001) \) (Fig. 6A). In addition, a strong positive correlation was found between HIV-1-specific IFN-γ/CD57+CD4+ and IFN-γ/CD57+CD8+ T cells when all HIV-infected subjects were evaluated \( (r = 0.88; p = 0.0003; \) Fig. 6B) as well as when only untreated HIV-1-infected patients were included in the analysis \( (r = 0.73; p = 0.04; \) data not shown). This association may indicate that the same virological factors independently drive CD57 expression on each cell type or may reflect direct interactions between CD57+CD4+ and CD57+CD8+ T cells.

To determine whether associations existed between CD57 expression on T cells and markers of HIV-1 disease progression, we next evaluated the relationships between frequencies of CD57+ T cells in the peripheral blood and either peripheral CD4+ T cell count or plasma HIV-1 viral load. No statistically significant correlations were found between total CD4+CD57+ T cells or HIV-1-specific CD4+CD57+ T cells and either viral load or CD4+ T cell count in HIV-1-infected subjects.

Discussion

Diminished virus-specific CD4+ T cell-proliferative responses are associated with uncontrolled viral replication and disease progression in both human and animal viral infections (19, 20, 28). Numerous studies (16, 17, 29) have documented that HIV-1-infected subjects have reduced CD4+ and CD8+ T cell-proliferative responses to recall as well as HIV-1 Ags. In this study, we characterize a population of CD4+ T cells, identified based on CD57 expression, that is both unable to proliferate in vitro and is expanded in the peripheral blood of HIV-1-infected subjects. We have previously shown that weak HIV-1-specific CD4+ T cell proliferation is associated with increased numbers of IFN-γ-producing, CCR7+CD45RA− effector memory CD4+ T cells (6). This current study demonstrates that increased expression of CD57 on CCR7+CD4+ T cells may be responsible for the diminished proliferative responses observed in viremic HIV-1-infected subjects. Furthermore, these data suggest that not only are CD4+ T cells skewed toward a CCR7− phenotype, as we have shown previously, but that distinct functional changes take place within this population in untreated subjects with progressive HIV-1 disease. This study expands on our previous findings by defining a novel subpopulation of CCR7−CD4+ T cells that express CD57, produce IFN-γ, and lack the ability to proliferate.

In concordance with studies of CD8+ T cells and NK cells expressing CD57, our results clearly demonstrate that CD4+ T cells expressing CD57 also proliferate poorly. In fact, when CD57+CD4+ T cells were sorted and stimulated with mitogen, little to no proliferation was detected, whereas the majority of both naive and memory CD57+CD4+ T cell populations vigorously divided. Very little down-regulation of CD57 was seen poststimulation, indicating that these cells do not readily change phenotype or regain the ability to proliferate after in vitro stimulation. These observations are supported by other studies, which demonstrate that CD57−CD8+ T cells are terminally differentiated, and that proliferation of these cells is not recovered even in the presence of IL-2 or IL-15 (8). Brenchley et al. (8) demonstrated that CD57 but not CCR7, CD28, or CD27 expression on CD8+ T cells correlated with diminished HIV-1-specific proliferation. Our results suggest that expression of CD57 on CD4+ T cells is a better marker of proliferation incompetence than CCR7 expression. Although studies have shown that the proliferative capacity of CCR7− T cells is
less than that of CCR7+ T cells, it is clear that some fraction of CCR7- cells are still capable of dividing. For example, a recent study (30) demonstrated that CMV-specific CCR7- T cells stimulated with their cognate peptide in concert with either CD4 help or IL-2 and IL-15 induced massive clonal expansion of these cells. Because CD57 is mainly expressed on CCR7- cells, our data suggest that the increased proportion of CD4+ T cells expressing CD57 may account for the reduced proliferation observed in HIV-1-specific IFN-γ-producing CCR7+ CD4+ T cells.

The percentage of peripheral blood CD4+ T cells expressing CD57 was significantly increased in HIV-1-infected subjects in this study. Increased frequencies of CD57+ T cells have been associated with a number of pathological conditions where Ag persists, such as Mycobacterium tuberculosis, rheumatoid arthritis, malaria, and HIV-1 (11–15). To determine whether there was an association between CD57 expression on CD4+ T cells and a decrease in HIV-1-specific proliferative responses, we studied two well-defined cohorts of HIV-1-infected subjects: untreated subjects with ongoing HIV-1 replication and ART-treated subjects with suppressed viral loads. These cohorts where chosen because it is well documented that HIV-1-specific proliferative responses are low to absent in untreated subjects with progressive disease, whereas improvement in proliferation is seen in a significant fraction of successfully ART-treated subjects who have detectable HIV-1-specific cytokine responses (6, 19, 20, 31). In this study, when HIV-1-specific CD4+ T cell responses were dissected into discrete cytokine-producing populations, we found that HIV-1-specific IFN-γ-producing T cells contained the highest percentage of CD57-expressing cells. This is in accordance with the finding that subjects whose HIV-1-specific response is skewed toward increased frequencies of CD4+ IFN-γ-producing T cells generally have the weakest proliferative responses (6). Interestingly, when CMV and SEB responses were analyzed, the percentage of IFN-γ-producing T cells expressing CD57 was similar to the fraction of HIV-1-specific, IFN-γ-producing CD4+ T cells that expressed CD57. Conversely, CD4+ T cells that produced IL-2 generally did not express CD57, again correlating with the known proliferative competence of these cells. These findings suggest that CD4+ T cells, which produce only IFN-γ, regardless of specificity, have increased CD57 expression, and that CD57 up-regulation may be a physiological response to persistent Ag exposure.

Chronic Ag exposure has been shown to drive T cells to a more differentiated effector memory state (7, 32). The expression of CD57 on CD8+ T cells has been associated with replicative senescence, shortened telomere lengths, and chronic activation due to persistent Ag exposure (7–9). Our data clearly show that CD57 is expressed to a greater degree on more differentiated CCR7- effector CD4+ T cells than on CCR7+ naive and Temc cells in both seronegative and HIV-1-infected subjects. Telomere lengths of CCR7-CD45RA- T cells are the shortest of the memory subsets, suggesting that they are the most differentiated (33), and increased frequencies of CCR7-, CD45RA-, virus-specific CD4+, and CD8+ T cells have been correlated with control of viral replication (33, 34). In this study, we observed increased CD57 expression on CCR7-CD45RA-CD4+ T cells (Temt) from untreated subjects with progressive disease (compared with seronegative subjects) and found a positive correlation between the percentage of peripheral blood CD57+CD4+ Temt and HIV-1 viral load (r = 0.53; p = 0.02; data not shown). These findings demonstrate that there are distinct phenotypic and functional changes within the effector memory CD4+ T cell population in subjects with untreated HIV-1 infection that may play a role in the loss of virological control. Support for this comes from the finding that hepatitis B- and C-specific CD8+ T cells share the same effector-memory phenotype (CCR7-, CD45RA-) but have striking functional differences and are associated with different clinical outcomes (35). HBV-specific CD8+ T cells have high perforin content and expand vigorously, whereas HCV-specific CD8+ T cells do not. Interestingly, increased frequencies of CCR7-, CD45RA-virus-specific CD4+, and CD8+ T cells have been correlated with control of viral replication (33, 34). These findings suggest that this important effector T cell population may be functionally impaired in untreated HIV-1-infected subjects and may play a role in the loss of virological control.

The finding that CD57 is mainly expressed on terminally differentiated memory CD4+ cells suggests CD57 expression may be used to identify “exhausted” cells. The lack of proliferation also suggests that these cells may have reached the point of replicative senescence. Very low TCR rearrangement excision circle levels and shortened telomere lengths in CD57+CD8+ T cells demonstrate that these cells have undergone extended rounds of replication. CD57+CD8+ T cells are also highly susceptible to activation-induced cell death (8). In concordance with the CD8+ T cell data, we found that CD57+ CD4+ T cells display a higher rate of spontaneous apoptosis and activation-induced apoptosis than CD4+ T cells not expressing CD57. The finding that CD57+CD4+ T cells cannot proliferate, exhibit increased rates of apoptosis, and are found mainly in the Temt memory subset indicate that, like CD57+CD8+ T cells, these cells have reached the end of their life span. The fact that increased percentages of CD57+CD4+ T cells were seen in untreated HIV-1-infected subjects is also in accord with the finding that there is significantly higher CD4+ T cell turnover in HIV-1-infected subjects (36, 37).

The impact that increased percentages of CD57+CD4+ T cells have on HIV-1 pathogenesis is unclear. Although CD4+ T cells that express CD57 are unable to proliferate or produce significant amounts of IL-2, they do produce IFN-γ and may be capable of cytolytic activity based on perforin production (7). It has been suggested that cytolytic CD57+CD4+ T cells are byproducts of inflammation and elevated activation, exhibiting increasing characteristics of replicative senescence and demonstrating cytotoxic potential for reasons still unclear (38). The question remains as to which type of HIV-1-specific CD4+ T cell response is most important for the control of chronic viral infection; one that provides help to virus-specific CD8+ T cells in the form of IL-2 and has the ability to self-renew, or one that directly kills virus-infected cells. The strongest evidence to date shows that HIV-1-specific CD4+ T cells that produce both IL-2 and IFN-γ correlate with virological control, whereas CD4+ T cells that produce only IFN-γ do not (4, 6, 39). Recently, it was shown that HIV-1-specific CD8+ T cell proliferation in chronically infected subjects was restored in vitro by the addition of autologous IL-2-producing HIV-specific CD4+ T cells (40). Our findings demonstrate a strong correlation between the percentage of CD57+ HIV-1-specific CD4+ and CD8+ T cells in the peripheral blood. One possible explanation for this association is that increased senescence in the CD8 compartment may result from an increased proportion of virus-specific CD57+ CD4+ T cells that produce only IFN-γ and not IL-2. These findings suggest that HIV-1-specific CD4+ CD57+ T cells that produce only IFN-γ may not provide adequate help to CD8+ T cells needed to mount a more effective CTL response.

Taken together, these data demonstrate that CD57 expression can be used to identify proliferation-incompetent CD4+ T cells, which these cells tend to accumulate in subjects with untreated HIV-1 disease, and that they persist after treatment. Elevated percentages of CD57+ T cells are found in the CCR7- effector populations of HIV-1-infected subjects, and expression is increased on IFN-γ-producing cells that have lost the ability to produce IL-2, suggesting that these cells may arise from chronic Ag exposure. HIV-1 and CMV-specific
IFN-γ-producing CD4+ T cells express similar levels of CD57, indicating that up-regulation of this marker may be physiological and used to identify exhausted cells. CD57+ T cells may contribute to HIV-1 disease pathogenesis, and examination of this population may be useful for determining the functional competence of the CD4+ T-cell compartment during infection with HIV-1 disease.

Acknowledgments

We thank the participants of this study for their cooperation. We also thank the physicians and staff of the University Hospital Infectious Diseases Group Practice for their assistance in recruiting and enrolling patients to this study. This work was supported by reagents provided through the National Institutes of Health AIDS Research and Reference Reagent Program.

Disclosures

The authors have no financial conflict of interest.

References